BioAtla Inc [BCAB] stock prices are up 12.86% to $2.37 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The BCAB shares have gain 18.50% over the last week, with a monthly amount glided 14.49%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
BioAtla Inc [NASDAQ: BCAB] stock has seen the most recent analyst activity on September 15, 2022, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $17. Previously, Credit Suisse downgraded its rating to Neutral on May 05, 2022, and dropped its price target to $5. On March 21, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $25 on the stock. ROTH Capital initiated its recommendation with a Buy and recommended $75 as its price target on June 28, 2021.
The stock price of BioAtla Inc [BCAB] has been fluctuating between $1.14 and $4.02 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. BioAtla Inc [NASDAQ: BCAB] shares were valued at $2.37 at the most recent close of the market. An investor can expect a potential return of 110.97% based on the average BCAB price forecast.
Analyzing the BCAB fundamentals
Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -6.79%, Pretax Profit Margin comes in at -5.61%, and Net Profit Margin reading is -5.61%. To continue investigating profitability, this company’s Return on Assets is posted at -1.14, Equity is -1.63 and Total Capital is -2.02. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.16 points at the first support level, and at 1.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.55, and for the 2nd resistance point, it is at 2.74.
Ratios To Look Out For
It’s worth pointing out that BioAtla Inc [NASDAQ:BCAB]’s Current Ratio is 3.11. On the other hand, the Quick Ratio is 3.11, and the Cash Ratio is 2.9. Considering the valuation of this stock, the price to sales ratio is 9.85, the price to book ratio is 4.99.
Transactions by insiders
Recent insider trading involved MCBRINN SYLVIA, Director, that happened on Dec 26 ’23 when 4000.0 shares were purchased. Chief Executive Officer, SHORT JAY M PHD completed a deal on Dec 20 ’23 to buy 50000.0 shares. Meanwhile, Director STEINMAN LAWRENCE bought 20000.0 shares on Dec 19 ’23.
